Kratom is under attack. We need to fight together to keep this miracle herb available and legal in the US.
What is kratom?
Where can I get it?
Why is it under attack?
American Kratom Association
Botanical Education Alliance
The Good. The Bad. The Ugly.
There is an insane amount of information floating around about kratom. We’ve done our absolute best to compile a list of sources including accurate information from all sides of the story. While we advocate for kratom, we also want to show the whole picture on what’s being said and done so here’s the good, the bad, and the ugly. Do your research and do what you think is right.
THE AMERICAN KRATOM ASSOCIATION STRONGLY ENDORSES DR. HENNINGFIELD'S REVIEW THAT QUESTIONS THE CONCLUSIONS RELATED TO KRATOM SAFETY IN THE EGGLESTON ET AL. BRIEF REPORT
Sign the Petition Asking President Trump to Appoint an FDA Commissioner who Will Follow the Science on Kratom
FDA Commissioner Scott Gottlieb’s incessant anti-kratom tweets, Public Health Alerts, and continued pleas to the Drug Enforcement Agency (DEA) to schedule kratom, take me back to the early 1990’s when the FDA’s similar attacks on vitamins and dietary supplements demonized any substance that could not be required to submit a new drug application. >> Read More
The facts are clear, twelve world-recognized Kratom experts that have come together to conclude Kratom is in fact safe. The proof is in a 25 page paper by Dr. Jack E. Henningfield. >> Read More
The American Kratom Association submitted an eleven-page letter and a petition signed by more than 40,000 Americans asking the U.S. Drug Enforcement Administration (DEA) to keep the current regulatory structure in place for kratom, a natural botanical in the coffee family native to Southeast Asia. >> Read More
You cannot pick up a newspaper or hear a news report out of Washington, DC that does not expose the bias held by rogue individuals within our government… >> Read More
Request comes after NIDA and the FDA remove information related to the safety of kratom from NIDA’s official website. Click here to read letter from NIDA director >>
Kratom (Mitragyna speciosa) is a tree-like plant indigenous to Southeast Asia. Its leaves, and the teas brewed from them have long been used by people in that region to stave off fatigue and to manage pain and opioid withdrawal. Evidence suggests kratom is being increasingly used by people in the United States and Europe for the self-management of opioid withdrawal and treatment of pain. Recent studies have confirmed that kratom and its chemical constituents have potentially useful pharmacological actions. >> LEARN MORE
CONCURRENCE BY THE HOUSE ON AMENDMENTS IS EXPECTED SOON, THEN ON TO THE GOVERNOR FOR SIGNATURE! Legislative Update: Mac Haddow, Senior Fellow on Public Policy – On Friday, May 24, the Nevada State Senate unanimously passed AB303, the Kratom Consumer Protection Act (KCPA) as amended, and it’s now headed back to the House for concurrence on amendments (none of which impacted the core consumer protections). >> LEARN MORE
Utah will become the first state to establish the correct regulatory framework for protecting consumers from dangerous adulterated kratom products and, at the same time, protect the freedom of Utah consumers to make their own choices on the use of natural products for their health and well-being. >> LEARN MORE
AMERICAN KRATOM ASSOCIATION ANNOUNCES MANUFACTURING STANDARDS TO PROTECT CONSUMERS FROM ADULTERATED KRATOM PRODUCTS
WASHINGTON, DC – August 14, 2018 – Peer-reviewed documentation concerning 44 deaths that the Food and Drug Administration (FDA) has cited to persuade the Drug Enforcement Administration (DEA) to place natural kratom… >> Read more
Kratom is under attack from the SITSA bill. The FDA has lobbied the Speaker of the House and they are trying to force the SITSA Bill to the House Floor without the amendment to protect Kratom from a back-door scheduling maneuver. CLICK TO CONTACT YOUR CONGRESSMAN
from Dave Herman, Board Chairman
In response to the latest FDA comment cautioning against the dangers of kratom, we kindly issue our response.